Sponsors (5)
This bill prioritizes lower drug prices, greater competition, and transparency by enabling price findings, open licensing, reporting, and enforcement — but does so at the risk of increased litigation, compliance costs, possible exposure of proprietary data, and potential downward pressure on pharmaceutical R&D and supply that could slow future innovation and create short‑term access/quality challenges.
Patients and public payers (including Medicare and Medicaid beneficiaries) will likely pay lower prices for many brand-name drugs because the bill enables excessive‑price determinations, open non‑exclusive licensing, capped royalties, and clearer price benchmarks.
People who need costly medicines (and hospitals/health systems) could see faster access to lower-cost generics and biosimilars because open licensing, caps, and an expedited FDA review pathway speed competitor entry.
Consumers, payers, researchers, and policymakers get far greater pricing and R&D transparency through public postings, annual detailed reports, and data on R&D/clinical spending, improving oversight and decisionmaking.
Pharmaceutical companies may reduce R&D investment or delay new drug development if revenue prospects fall, which could slow the arrival of future therapies and harm patients long‑term.
Manufacturers could respond in the short term by raising launch prices, limiting U.S. supply, or curtailing collaborations to avoid enforcement risk, which may reduce access or increase costs for some drugs.
Government excessive‑price findings, use of competitor regulatory data, and public naming are likely to provoke legal challenges and administrative disputes that delay implementation and impose litigation costs on taxpayers and agencies.
Based on analysis of 8 sections of legislative text.
Authorizes HHS to find brand drug prices "excessive," void statutory exclusivities, issue open non-exclusive licenses, set royalties, require manufacturer reporting, and impose penalties.
Official title: To significantly lower prescription drug prices for patients in the United States by ending government-granted monopolies for manufacturers who charge drug prices that are higher than the median prices at which the drugs are available in other countries.
Introduced May 21, 2025 by Ro Khanna · Last progress May 21, 2025
Creates a federal process for identifying brand-name drugs with “excessive” U.S. prices, terminates certain government-granted exclusivities for those drugs, and authorizes open, non-exclusive licenses so other firms can make, import, and sell lower-cost generics or biosimilars. It requires annual manufacturer price-and-cost reporting, directs the HHS Secretary to set royalties that keep prices affordable, posts a public database of determinations, and authorizes civil penalties and FTC-style anticompetitive enforcement to protect competition.